was established in July 2015 with a registered capital of 10 million yuan. The company focuses on the development and commercialization of vascular health products, including cardiovascular, cerebrovascular, peripheral vascular and other consumables. The core team of the company comes from well-known medical device enterprises at home and abroad, covering all levels of technology, production, quality, regulations, market and sales, and has a large number of industry elites. Through team self-financing and angel round financing, the company has obtained 8 million startup funds for GMP plant construction and equipment raw material procurement.

Suzhou Highwire medical equipment co., LTD., established in September 2013 in biological nanometer park, has a registered capital of 10 million yuan, mainly developing high-end medical guides such as zebra guide wire and loach guide wire with independent intellectual property rights and various types of minimally invasive surgical instruments and consumables.

The company has completed about 1,400 square meters (including GMP cleaning workshop) of the workshop decoration, on the one hand started to undertake B2B orders, its customers have been sold in the clinical market, mainly for cardiovascular, peripheral blood tube, urology, digestive tract, gynecology, such as Beijing lepu, shandong xinhua; On the other hand, the company independent development of the thread, as part of a customer declaration registration certificate of medical equipment products, is also in accordance with the new regulations on the medical device regulatory, the province food safety of medical equipment, apparatus, the institute of care and guidance, to declare four second class and two types of medical equipment product registration certificate; At the same time, it has passed the European Union's 13485 system certification and CE certification.

Established on March 30, 2016, Guanjie medical technology (suzhou) co., ltd. is a sino-foreign joint venture medical device r&d and production company, registered in C21 building of suzhou industrial park biological medicine industrial park, with registered capital of 2.75 million us dollars and total investment of 5 million us dollars.

Guanjie medical technology (suzhou) co., LTD. Is mainly engaged in the research, development and production of artificial minimally invasive interventional cardiac mitral valve membrane. The company is founded by three partners: Dr. Zhang ji, founder, chairman and general manager of the company, doctor of medicine, university of Toronto, Canada. Dr. Zhang was not only selected as "leading talent of innovation and entrepreneurship of gusu", "leading talent of science and technology of double hundred in jinjihu", but also won the "top ten charming science and technology figures of suzhou".

Dr. Yang chengyong, founder of the company, doctor of pharmacy, purdue university. Dr Yang started his career in various pharmaceutical companies in silicon valley, has broad medical development background and the enterprise management with many years of accumulated experience, is a renal cell carcinoma and gastrointestinal cancer drug resistance SUTENT core research and development personnel, is also a main founder of the two kinds of hepatitis b virus drugs, has been involved in the application of pharmaceutical products to the FDA. Brandon g. Walsh, founder and chief engineer. Mr. Walsh graduated from the University of Utah, Salt Lake City and worked as a senior research and development engineer for several pharmaceutical companies in the United States.

HOB Biotech Group is a leading manufacturer in China and has emerged as a first-class global company in allergy and autoimmune in vitro diagnostics.

In 2007, entrepreneurs with education and decades of industrial experience in the US started to distribute American and European products in China. HOB has since established a large-scale, ISO 13485 certified manufacturing facility in Suzhou, China, producing high quality products for Asian markets ranging from Line Immuno Assay (BioLINE) to Enzyme-linked immunosorbent assay (BioLISA). HOB has further established world-class R&D centers in Suzhou, China and California, US, with a well experienced product development team which is up to 60 employees by far and led by scientists with education and decades of R&D experience in IVD diagnosis.

By 2018, with years of dedicated research and efforts, HOB has successfully launched its first fully automated quantitative chemiluminescence analyzer with the most comprehensive autoimmunity menu in China market, known as BioCLIA. BioCLIA implements the most cutting-edge technologies that are available in the autoimmunity diagnostics. In the first five months of 2018, HOB sales grow more than 40% yoy and BioCLIA has become one of the most competitive product lines with the fastest sales growing rate of the company.

HOB competes against the well-known companies from US and Germany who dominated the market not by prices, but through its fundamental paradigm shift into emphasizing quality manufacturing and intensive R&D investment. HOB has arisen into the allergy & autoimmune diagnostic market leader in Asia and a global player in the IVD industry.

HOB’s mission is to establish and offer customers a top-tier brand in allergy and autoimmune in vitro diagnostics, with state-of-art technologies, the topnotch quality, and the competitive prices. As a leading manufacturer with strong R&D capability, HOB is expanding its global influence by forming strategic alliances with companies worldwide to provide advanced technology and the most competitive products.

Established in November 2014 with a registered capital of 10 million yuan, Jiangsu Okani medical technology development co., ltd. is an innovative r&d and manufacturing enterprise focusing on the field of orthopaedic implants, especially new materials and new technologies for artificial joints. Company's "new type of artificial joint project" condensed the strong scientific research team, including the ninth people's hospital affiliated to Shanghai jiaotong university school of medicine, people's hospital affiliated to Peking University, China mining university, institute of metal research institute, tsinghua university, Chinese academy of sciences, China (shenzhen), orthopaedic institute of suzhou university, tianjin test center, etc from the domestic authority. The main researchers in the team include academicians of the national academy of engineering, top engineering designers of orthopaedic clinicians, doctors and masters in mechanical engineering, materials science, biological tribology, orthopedics and other professional fields, to create a new artificial joint brand!

Established in July 2008 in suzhou industrial park, Suzhou Biovention medical technology co., ltd. mainly produces medical devices related to heart vessels, especially the implantable artificial organs and the scientific and technological products combining drugs with artificial organs. The company's first innovative product: innovation-drug-eluting coronary stent system technology has been granted two us patents (patent number: US7438925B2; US 8,357,386), authorized two Chinese patents (patent number: 03818546.6, patent number: 200680008362.9).

Jiangsu FengYuan medical equipment co., ltd. was established in May 2015 with a registered capital of 80 million yuan and was founded by Xi tingfei, a leading talent in suzhou industrial park. Adhering to the entrepreneurial concept of "pursuing development through innovation" and backed by Peking University, the company is committed to the research and development and industrialization of full-degradation coronary stents and cardiovascular and cerebrovascular medical devices.

The company has developed a new type of full-degradation magnesium alloy stent with independent intellectual property rights in China. In the preimplantation experiment of the pig coronary artery, after 1, 3 and 6 months of stent implantation, the vascular patency is good, the endothelialization is good, the proliferation of vascular smooth muscle is less, and the inflammatory reaction is not obvious. The results show that the fully degraded magnesium alloy coronary stent has reached the international advanced level. The company intends to complete the type test and animal experiment of magnesium alloy coronary stent by the end of the year, and complete the clinical trial of 1,230 cases by the end of 2019.

Suzhou Gene+ biomedical engineering co., LTD. focuses on the field of tumor gene detection, mainly engaged in the research, development, production and sales of tumor in vitro diagnostic reagents and related medical detection instruments. In suzhou, there are nearly 4000 in vitro diagnostic workshops. With an integrated platform focusing on r&d, production, quality management and after-sales service and a professional technical core team, as well as a testing center in the eastern region of jinjia, we will provide professional and personalized precise tumor detection services.

CareRay is dedicated to the innovation and production of the newest generation of flat panel detectors for medical, veterinary, security and industrial digital X-ray imaging systems.

Our Mission

CareRay excels at developing and manufacturing high-performance cesium iodide (CsI) direct deposition detectors and offers a complete line of sizes of fixed, portable and wireless models.

CareRay’s award winning R&D team of experts has created more than a dozen significant technology patents, which CareRay uses to produce superior flat panel detectors for the global market.

Through the pursuit of excellence, optimized engineering and disciplined fabrication processes, CareRay provides customers with advanced, robust, user-friendly flat panel detectors and software.

Our mission as a technology innovator and international supplier is to revolutionize diagnostic imaging by sharing the benefits of our scientific and functional advances.

We welcome your enquiries on our product line, our customized production programs and our latest R&D break-throughs!

Sceneray Co. Ltd, located at Singapore Industrial Park in Suzhou China, is a leading medical device company dedicated to the design, Development, and distribution of neuromodulation devices. The core team of Sceneray is made up by experts with deep China and overseas experiences in neuromodulation device development, manufacturing, and marketing. Sceneray holds many patents and keeps on exploring the frontiers in neuromodulation. Being an international high-tech medical and competitive company, Sceneray is dedicated to providing patients with high-quality and efficacious treatments.

 The Research & development team of Sceneray was built up in July 2009. The team has already obtained 152 patents till now, including six patents of the United States. At the same time, the team successively has accomplished the design and test of deep brain stimulation (DBS), performance validation of DBS, DBS animal experiments based on Rhesus and clinical trial in multi-centers of China.

 The innovative technology and performance of Sceneray DBS is ahead of similar products in domestic and foreign areas. In 2014, Sceneray DBS firstly got the access to enter the Innovation Special Project Approval Process of Chinese Food and Drug Administration (CFDA). In June 2015, Sceneray DBS obtained the registration of CFDA.

Tonkbio is focusing on bio-pharmaceutical & health industry for 9 years and now becomes a professional biological enterprise with advantages of researching and developing innovative drugs and reagents by grabbing the great opportunity of the rapid development of life medicine research and the growth of clinical diagnosis market. Meanwhile we obtained great competitiveness in the field of medical services after 9-year effort.

Now more than 25,000 customers from pharmaceutical companies, universities, hospitals, research institutions and government organizations are using our enzymes, cell factors and PCR mixes & kits. Our mission is to best serve worldwide scientists in life science industry by offering best-in-class products with lowest cost. We hope our 9-year-effort will help to move your research forward in a cost-effective way. We believe that you would gain the most for your study by making the best use of what we supply.

Suzhou Ruiyan Nano Medical Technology Co., Ltd. is a high-tech company specializing in R&D, application, production and technical consulting services for nano and bio-regeneration medical products. The company is located in Zhong Ling Yuk Sau, outstanding people of the Suzhou Industrial Park, R & D team by senior scientists from North America and China well-known universities of the composition, has many years of precipitation technology in biomaterials, biomedical engineering, has completed CleanSur ®  medical antibacterial drop deposition and anti-bacterial organisms Membrane coating technology, CleanMed ®  specific antibacterial care solution, CleanFab ®  zero release contact antibacterial coating technology, CleanGlu TM fast hemostatic antibacterial double effect gel, CleanWeb TM  ultrafine nanofiber membrane manufacturing technology and many other products and technologies Industrialization, and obtained relevant invention patents. At the same time, the company has a technical reserve in the field of regenerative medicine such as artificial blood vessels and brain damage repair.

At the beginning of 2012, the company was formally incorporated. In just over a year, we have received funding from the “First Nano-Leading Talents” program of Suzhou Industrial Park; Jiangsu Science and Technology Support Program Project Funding, China-Singapore Venture Capital and Park Guidance Fund Venture Capital The first place in the national “First Thousand Talents Entrepreneurship Competition”. The company has entered a rapid development channel.

JOUSING is located in the Biomedical Industrial Park of Suzhou Industrial Park. It is a professional provider of pre-hospital products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights. The park has led the talent leadership program.

Founded in 2007, NUHIGHBIO focusing on the development of nucleic acid molecule detection and related technology applications. The company has a number of qualifications such as “National High-tech Enterprise”, “Science and Technology-based SMEs in Jiangsu Province” and “Suzhou-based R&D Institutions”. The company has established GMP factory in line with national standards and has passed ISO9001, ISO13485 quality management system certification. The company was listed on the New Third Board at the end of 2015 (stock code: 834513).

NUHIGHBIO has cooperated with the Ministry of Public Security forensic identification center for a long time. It has taken the lead in developing forensic DNA reagents in China and applied it to the construction of forensic DNA database, which greatly promoted the development and application of forensic DNA technology in China, and also enabled China to have it in 2011. The world's largest forensic DNA database has played a huge role in promoting high-tech police. NUHIGHBIO's forensic DNA products include chemically modified hot start enzymes, fluorescent energy transfer primers, internal standards, FTA sample collection cards, and FTA card direct expansion reagents, all of which have reached or advanced the world's advanced levels.

In addition to continuing to develop new technologies and products in the field of forensic DNA, NUHIGHBIO has begun to expand into the field of medical nucleic acid molecule detection, and has developed the first CTDNA detection technology at home and abroad.

The company has a number of patented technologies (including patents in China, the United States, the European Union, Brazil, India, etc.), market-oriented, application-oriented, pragmatic innovation, development of new products, continuous enhancement of comprehensive strength and ultimately leading technology and market is always the new sea Such as the development goals.

Kolo Medical is the world leader in the next generation of semiconductor ultrasound technology.  Our innovative design and patented approach with Capacitive Micromachined Transducers (CMUT) are establishing a new performance standard in medical diagnostic imaging.  This unique approach in overcoming the challenges of CMUT technology establishes Kolo Medical as a leader in offering a suite of commercially available transducers, and ushers in the dawn of the silicon age of ultrasound imaging.

We offer a portfolio of SiliconWaveTM transducers available for a wide range of platforms to clinical and research markets.  Our technology establishes exceptional performance for high and ultra high frequency imaging, imaging traditional PZT technology struggles to provide.

Suzhou SyMap Medical Ltd is located at Suzhou bioBAY as an innovative medical device company. The company is founded by an excellent team with outstanding reputation and exceptional experience in cardiovascular medical device field in both China and US. SyMap is dedicated to developing a proprietary catheter-based renal mapping and ablation system for renal denervation therapy to treat hypertension and other diseases, such as heart failure, arrhythmia, renal failure, diabetics and sleep apnea, etc. Our novel renal mapping and ablation technology optimizes the delivery of renal denervation, significantly improves responder rate to the therapy, and can be also used to assess whether an efficient ablation is delivered for renal sympathetic denervation. The unique position of SyMap in renal denervation field is protected by a portfolio of IPs (pending), and the proprietary technology platform of SyMap has been granted with USA CRT2012 Best Innovation Award.

Founded in 2008, Realton is a high-tech medical enterprise under the healthcare industry giants with independent intellectual property rights and product patents. Realton is an enterprise with core competitiveness in the field of medical laser equipment and high-value consumables. Currently, its products cover more than 80% provinces in mainland China. Realton 's main products are 120 watt, 140 watt, 160 watt, 180 watt green laser operating system and a variety of specifications of high quality disposable medical optical fiber.

Realton products focus on male benign prostatic hyperplasia of minimally invasive surgery treatment, product core green laser technology has "indications wider, higher operation efficiency, better postoperative complications" advantage, will be to replace the traditional men, the urethra prostate electricity cut method of minimally invasive surgical treatment of BPH "gold standard".

With the mission of " Realton -- dedicated to creating high-quality life", Realton company continuously optimizes the product portfolio and continuously launches innovative products to serve patients and doctors. Realton is a firm believer that innovation is the foundation of competitiveness, the source of development, and the key to future success.

Adhering to the corporate culture and core values of "customer first, result oriented, simple action, quality first, and win-win cooperation", Realton continuously promotes the vigorous development of China's medical and health cause.

Suzhou innomed Medical Device Co.,Ltd is a high-tech enterprise engaged in the development and production of medical Device. Including medical Device development,production,independent design,verification and other technical outsourcing services. The company was established in January, 2013 with ¥11.2 million Registered capital. It is located in the BioBAY, Suzhou Industrial Park, Jiangsu province.

Innomed has deep research and development experience in peripheral blood tube equipment and high-end consumables field. It's cardiovascular guidewire will enter the Chinese market and break the monopoly of imported products in this field. Innomed has a strong technical team which is recognized by the industry. The founder PhD Xiaoyan Gong was once a chief engineer of Johnson, and also the founder of he former American MIM company. Dr Gong was rewarded with National "Thousand People Plan"Expert, "High level innovation and entrepreneurship talent introduction plan in Jiangsu", "Gusu district talent program", "Suzhou industrial park leading talent" and so on. Innomed now has four overseas returnee, Six masters, Over 40 employees. The  R&D and manufacturing teams have unique skills in vascular stent design, manufacturing process, fatigue testing and durability assessment. The Peripheral vascular stent system Inno-Spring which is underdevelopment won the 2016 product design red dot award. The product has passed the special approval application of innovative medical device and is about to enter clinical.

Innomed has a class of clean plant, and nearly 1000 square meters R&D and office space. Innomed has reached a good long-term relationship with many well-known colleges and universities, enterprises and hospitals.Currently, Innomed has applied for More than 50 national inventions, patent for utility models, a number of PCT patents and U.S.patents. 22 items have been authorized (5 patents for invention) and 28 have been submitted. In addition, national key research anddevelopment projects and other projects are also in the declaration.

Innomed will take the market and R&D as the driving force and build a platform for scientific and technological innovation, and constantly introduce innovative medical devices with independent intellectual property. 

First Dimension is a company focusing on digital life and genetic big data. The company aims to transform gene sequence information into the Gospel of human's pursuit of health and victory over diseases. With cancer detection as the starting point, the first gene can provide useful information for early cancer screening, auxiliary diagnosis, drug guidance and prognosis tracking through bioinformatics analysis, so as to bring maximum treatment effect to cancer patients.

The first Dimension has a professional research and development team that has been engaged in gene detection and big data analysis for many years. Through the most advanced testing equipment in the industry, the company comprehensively uses the self-developed high-sensitivity capture method and refined experimental method to build a world-class biological information data center. The first Dimension aims to build an authoritative database of cancer gene information in China, create a statistically significant baseline of common cancer variation and treatment effect among Chinese people, and aim to become a leader in China's genetic big data industry.

The first Dimension will also provide free database resources for cancer genomics researchers through China cancer cloud platform, a public data platform, jointly promote the development of analysis and research in the field of cancer genes, and constantly improve the big data of cancer genes that are helpful to patients' treatment.

The first Dimension provides a wide range of biological information analysis services starting from genetic detection of cancer and liquid biopsy. Committed to cancer prevention, diagnosis and improved treatment, the company has built an integrated solution based on high-throughput gene sequencing technology and big data analysis platform.

NeuInvent Inc. (Suzhou) is rooted from NeuroInvent Inc.(US) which is a California Silicon Valley based medical device company. Its core members are group of physician scientists from the field of neurophysiology, neurology and neurosurgery. Company’s innovational products focus on improving surgical accuracy in operating nerve systems including neurosurgeries, orthopedic surgeries, ENT, and rehab, etc., especially minimal invasive surgeries. Our products are clinical driven combining with high technology and superior user experience. 

        NeuInvent Inc. (Suzhou) is aiming on a growing market in China that urgently needs its own innovational medical devices in a leading position in national and global market. NeuInvent Inc. (Suzhou) is bringing new model of neural functional monitoring system and patented surgical devices into China market.